The issue of immunology in stem cell therapies: a pharmaceutical perspective

Free to access editorial from the Special Focus Issue of Regenerative Medicine by Richard Haworth and Michaela Sharpe

Go to the profile of Regenerative Medicine
Jun 05, 2015

“...immunological privilege does not mean lack of immune response..."

As increasing numbers of stem cell therapies are entering clinical trials, the issue of the immunological consequences of these therapies has not kept pace with our knowledge of their cell biology. In simple terms, the immunological questions for stem cell derived therapies can be divided into three categories; the properties of the administered cells, the relative immune tolerance of the site of administration and the immune status of the host or patient.

By Richard Haworth (GSK) and Michaela Sharpe (Cell Therapy Catapult)

You can read the full Editorial here.

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (, where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.